ArticleBMC infectious diseases2026
B cell immune response to Talaromyces marneffei infection in HIV-negative patients and rat models.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
purposeTalaromyces marneffei (T. marneffei), a thermally dimorphic fungus, causes systemic mycosis, with pathogenesis involving intracellular survival and dysregulation of host immunity. This study investigates the phenotypic and functional alterations in B lymphocytes induced by T. marneffei infection.
methodsRetrospective analysis of peripheral blood B cell counts and IgG/IgM levels in 31 HIV-negative Talaromycosis (TSM) patients. Peripheral blood samples were collected to measure plasmablasts, plasma cells and related cytokine expression. The plasmablasts and plasma cells in spleen was determined using flow cytometry in T. marneffei infected rat models, and the levels of IgG/IgM, B-cell activating factor (BAFF), A Proliferation-Inducing Ligand (APRIL) and IL-21 were determined.
resultsTSM patients exhibited reduced CD19⁺B cell and plasmablasts proportions in peripheral blood, while plasma cell proportions increased significantly and IgG, IgM levels in serum were elevated. In T. marneffei infected rats, the proportion of plasmablasts and plasma cells in splenic lymphocytes increased, and levels of IgG, IgM, BAFF, APRIL and IL-21 were significantly elevated compared to normal control rats.
conclusionT. marneffei infection induces B-cell phenotypic and functional abnormalities, manifested as reduced B-cell numbers, increased proportions of plasma cells, accompanied by upregulation of BAFF, APRIL, and IL-21 expression. This suggests T. marneffei may participate in pathogenesis by regulating B-cell differentiation and humoral immune responses. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.